UK Multiomics Market (2026-2031)
The UK Multiomics Market was valued at $165.6 Million in 2026 and projected to reach to $296.9 Million by 2031, representing a compound annual growth rate of 12.4%. The UK multiomics market is poised for sustained expansion driven by increasing adoption within the NHS and growing demand for precision medicine solutions.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
UK Multiomics Market Trends and Insights
- The UK's advanced healthcare infrastructure and strong investment in precision medicine are driving adoption of multiomics technologies across research institutions and clinical settings.
- The UK's regulatory environment and NHS integration are accelerating the deployment of integrated genomic, proteomic, and metabolomic solutions. During the 2026-2031 forecast period, the UK multiomics market will benefit from increased funding for genomic research and growing demand for personalized treatment approaches.
- The UK's position as a life sciences hub attracts both domestic and international players, fostering innovation in multiomics platforms.
- Healthcare providers across the UK are increasingly recognizing the value of multiomics data in disease diagnosis, drug development, and patient stratification, positioning the market for sustained expansion..
Key Market Statistics
- CAGR (2026-2031) 12.4% CAGR
- Market Size, 2026 ~USD 165.6 Million
- Forecast, 2031 ~USD 296.9 Million
- Country UK
UK Multiomics Market Overview
Market Valuation Growth :
The UK multiomics market is valued at £165.6 million in 2026 and is projected to reach £296.9 million by 2031, representing a robust 12.4% CAGR over the forecast period.
NHS Integration Driving Adoption :
The National Health Service's integration of multiomics technologies into clinical pathways is accelerating market penetration across UK hospitals and diagnostic centres, improving precision medicine capabilities.
Research Institution Investment :
UK universities and research institutions are significantly investing in multiomics infrastructure, supported by government funding and private sector partnerships, positioning the UK as a European innovation hub.
Regulatory Advantage :
The UK's streamlined regulatory environment and post-Brexit flexibility enable faster approval and implementation of multiomics diagnostic solutions compared to other European markets.
UK Multiomics Market Dynamics
- Advanced healthcare infrastructure, coupled with substantial government investment in genomic medicine initiatives, creates a favourable environment for multiomics technology deployment.
- The UK's position as a leader in life sciences research and development further supports market growth.
- By 2031, multiomics is expected to become integral to clinical diagnostics and treatment planning across oncology, cardiology, and rare disease management, with NHS trusts increasingly leveraging these technologies to improve patient outcomes and reduce healthcare costs..
Market Ecosystem
MULTIOMICS MARKET: COMMERCIAL USE CASES ACROSS INDUSTRIES
| COMPANY | USE CASE DESCRIPTION | BENEFITS |
|---|---|---|
 |
Provides Illumina Connected Multiomics, a cloud-based platform that integrates and analyzes genomics, transcriptomics, proteomics, epigenomics, and other multiomic datasets. For example, oncology researchers at the University of Colorado Anschutz Medical Campus used the platform to analyze proteomic data and generate insights into melanoma biology. | Enables integrated analysis of multiple biological data layers, helping researchers identify biomarkers, understand disease mechanisms, and accelerate precision medicine and drug discovery. (Illumina) |
 |
Provides Chromium Single Cell Multiome ATAC + Gene Expression technology, enabling simultaneous profiling of chromatin accessibility and gene expression in individual cells. Its platforms are widely used in cancer, immunology, and developmental biology research to characterize cellular states and regulatory mechanisms. | Provides a comprehensive view of gene regulation at single-cell resolution, helping researchers link regulatory elements with gene expression and identify disease-associated cell populations. |
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
Related Ecosystem
Biotechnology
- Reagents
- Polymerase Chain Reaction (PCR)
- Stem Cells
- Assay Kits
- Flow Cytometers
- Thermo Fisher Scientific Inc.
- Merck KGaA
- Danaher Corporation
- Agilent Technologies, Inc.
- Bio-Rad Laboratories, Inc.
Key Takeaways
- The UK multiomics market is projected to grow from £165.6M (2026) to £296.9M (2031) at a 12.4% CAGR.
- The UK's NHS integration and precision medicine initiatives are key drivers of multiomics adoption.
- The UK's life sciences ecosystem attracts significant R&D investment and international partnerships.
- Clinical applications in disease diagnosis and personalized medicine are expanding rapidly across the UK.
Multiomics Market Report Scope
| Report Metric | Details |
|---|---|
| Base Year | 2026 |
| Fastest Growing Segment | SERVICES (Offering) |
| Forecast Period | 2026-2031 |
| Growth Rate | CAGR of 12.3% from 2026 to 2031 |
| Largest Segment | PRODUCTS (Offering) |
| Market Size Base Year (Billions) | ~USD 3.19 (2026) |
| Revenue Forecast (Billions) | ~USD 5.7 (2031) |
| Segments Covered | Offering, Type, Technology, Method, Workflow, Application, End User |
UK Multiomics Market Report Segmentation
7 segment dimensions are covered across the global market.
By Offering
- Products
- Services
By Type
- Assay Kits & Reagents
- Consumables
- Instruments & Software
- Long-Read Sequencing
- Ms-Based Proteomics
- Nanopore Sequencing
- Ngs-Based Proteomics
- Other Consumables
- Other Proteomics Methods
- Other Sequencing Technologies
- Pcr-Based Proteomics
- Smrt Sequencing
By Technology
- Long-Read Sequencing
- Nanopore Sequencing
- Other Sequencing Technologies
- Other Technologies
- Proteomics
- Sequencing
- Smrt Sequencing
By Method
- Chromatin Accessibility Sequencing
- Chromatin Interaction Analysis
- Dna Methylation Sequencing
- Epigenomics
- Histone Modification Profiling
- Long-Range Sequencing
- Long-Read & Long-Range Sequencing
- Long-Read Sequencing
- Ms-Based Proteomics
- Ngs-Based Proteomics
- Other Epigenomics Methods
- Other Long-Read & Long-Range Sequencing Methods
- Other Methods
- Other Proteomics Methods
- Other Single-Cell Omics
- Other Spatial Omics
- Pcr-Based Proteomics
- Proteomics
- Sequencing-Based Epigenomics
- Single-Cell Epigenomics
- Single-Cell Genomics
- Single-Cell Omics
- Single-Cell Proteomics
- Single-Cell Transcriptomics
- Spatial Epigenomics
- Spatial Genomics
- Spatial Omics
- Spatial Proteomics
- Spatial Transcriptomics
By Workflow
- Data Visualization & Analysis
- Sample Preparation
- Sequencing & Analysis/ Sample Characterization
- Sequencing & Analysis/Sample Characterization
By Application
- Biomarker Discovery
- Cell Biology
- Clinical Diagnostics
- Drug Discovery & Development
- Immunology
- Neurology
- Oncology
- Other Applications
- Precision Medicine
- Translational Research
By End User
- Academic & Research Institutes
- Cros & Cdmos
- Hospitals & Diagnostic/Clinical Laboratories
- Pharmaceutical & Biotechnology Companies
Target Audience
- NHS Procurement Teams : Need market data to evaluate multiomics technology vendors, assess budget allocation, and make informed purchasing decisions for hospital diagnostic departments.
- Biotech & Diagnostics Companies : Require UK-specific market intelligence to develop go-to-market strategies, identify partnership opportunities with NHS trusts, and forecast revenue potential in the British market.
- Research Institutions & Universities : Seek market insights to justify funding applications, identify collaboration opportunities, and understand the commercial landscape surrounding their multiomics research initiatives.
- Healthcare Investors & Venture Capitalists : Need comprehensive market analysis to evaluate investment opportunities in UK-based multiomics companies and assess sector growth potential and exit opportunities.
- Healthcare Consultants & Strategy Firms : Require detailed UK market data to advise clients on market entry, competitive positioning, and strategic planning within the rapidly evolving multiomics healthcare sector.
Reasons to Buy this Report
- NHS Market Opportunity : Understand how NHS integration is reshaping the UK multiomics landscape and identify opportunities to supply diagnostic solutions to the largest healthcare provider in the country.
- Competitive Landscape Intelligence : Gain detailed insights into UK-based and international competitors operating in the multiomics space, including their market positioning, partnerships, and strategic initiatives.
- Regulatory Pathway Clarity : Navigate the UK's unique post-Brexit regulatory environment with comprehensive guidance on approval processes, compliance requirements, and market entry strategies specific to British standards.
- Investment & Funding Trends : Identify key funding sources, government grants, and venture capital activity in the UK multiomics sector to support business development and partnership strategies.
- Clinical Application Insights : Discover which therapeutic areas and clinical settings are driving multiomics adoption across the UK, enabling targeted product development and market penetration strategies.
Frequently asked questions
What is the current size of the UK multiomics market?
The UK multiomics market was valued at £165.6 million in 2026 and is expected to reach £296.9 million by 2031.
What is the growth rate of the UK multiomics market?
The UK multiomics market is growing at a compound annual growth rate (CAGR) of 12.4% from 2026 to 2031.
What factors are driving growth in the UK multiomics market?
Key drivers include NHS integration, precision medicine initiatives, increased genomic research funding, and growing demand for personalized treatment approaches across UK healthcare providers.
How is the UK positioned in the global multiomics market?
The UK is a leading life sciences hub with advanced healthcare infrastructure, strong regulatory frameworks, and significant R&D investment, attracting both domestic and international multiomics players.
What are the main applications of multiomics in the UK?
Primary applications in the UK include disease diagnosis, drug development, patient stratification, and personalized medicine across clinical and research settings.
RESEARCH METHODOLOGY
This study involved four major activities in estimating the current size of the multiomics market. Exhaustive secondary research was conducted to gather information on the market, its peer markets, and its parent market. These findings, assumptions, and sizing were then validated with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. Following this, the data triangulation procedure was used to estimate the market size of segments and subsegments.
Secondary Research
Secondary research was primarily used to identify and gather information for the extensive, technical, market-oriented, and commercial study. The secondary sources referred for this research study include publications from government sources, such as the National Institutes of Health (NIH), National Center for Biotechnology Information (NCBI), European Bioinformatics Institute (EMBL-EBI), US Food and Drug Administration (FDA), European Medicines Agency (EMA), World Health Organization (WHO), and Organisation for Economic Co-operation and Development (OECD). Omics-specific repositories and research initiatives, including Human Protein Atlas, the Cancer Genome Atlas (TCGA), Genotype-Tissue Expression (GTEx), Clinical Proteomic Tumor Analysis Consortium (CPTAC), among several others. Secondary sources also included corporate and regulatory filings (such as annual reports, SEC filings, investor presentations, and financial statements); business magazines and research journals; press releases; and trade, business, and professional associations. These sources were also used to obtain key information on major players, global product revenues, market classification, and segmentation by industry trends, regional/country-level markets, market developments, and technology perspectives. Secondary data were collected and analyzed to determine the overall size of the global Multiomics market, and the findings were validated through primary research.
Primary Research
In-depth interviews were conducted with primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among others, to obtain and verify critical qualitative and quantitative information and assess market prospects. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information. The following is a breakdown of the primary respondents:
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
The global size of the multiomics market was estimated through multiple approaches. A detailed market estimation approach was used to estimate and validate the market value and other dependent submarkets. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
Multiomics Market : Top-Down and Bottom-Up Approach
Data Triangulation
After estimating the overall market size from the market size estimation process, the total market was split into several segments. To complete the overall market engineering process and arrive at the exact statistics for all segments, the data triangulation procedure was employed; it involved studying various factors and trends from both the demand and supply sides.
Market Definition
The multiomics market comprises commercial revenues generated from products and services used to perform integrated multiomics analyses by combining two or more molecular profiling modalities, such as genomics, epigenomics, transcriptomics, proteomics, and spatial or single-cell omics. The market includes instruments, software, assay kits, reagents, consumables, and analytical services supporting advanced multiomics workflows from sample preparation and molecular characterization to data integration, visualization, and interpretation. These technologies are used across research and clinical applications, including oncology, precision medicine, biomarker discovery, translational research, drug discovery, and clinical diagnostics, by pharmaceutical and biotechnology companies, academic and research institutions, hospitals, diagnostic laboratories, CROs, and CDMOs. The market excludes conventional single-omics technologies, routine short-read sequencing workflows, microarray-based molecular profiling, and general laboratory products not specifically designed for integrated multiomics applications.
Key Stakeholders
- Multiomics product & service providers
- Multiomics bioinformatics/data analysis companies
- Venture capitalists and other government funding organizations
- Research and consulting firms
- Hospitals and diagnostic clinics
- Pharmaceutical and biotechnology companies
- Academic and government research institutes
- Life science companies
Report Objectives
- To define, describe, and forecast the multiomics market by offering, method, technology, workflow, application, end user, and region
- To provide detailed information regarding the major factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
- To analyze the micromarkets with respect to individual growth trends, prospects, and contributions to the overall multiomics market
- To analyze the opportunities for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of the market segments with respect to six regions: North America (US and Canada), Europe (Germany, France, the UK, Italy, Spain, and the Rest of Europe), Asia Pacific (China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific), Latin America (Brazil, Mexico, Argentina, and the Rest of Latin America), the Middle East [GCC Countries (Saudi Arabia (KSA), United Arab Emirates (UAE), and the Rest of GCC Countries) and the Rest of Middle East], and Africa
- To profile the key players and analyze their market shares and core competencies
- To track and analyze competitive developments, such as product launches, partnerships, agreements, collaborations, and expansions
- To benchmark players within the market using the proprietary “Company Evaluation Matrix” framework, which analyzes market players on various parameters within the broad categories of business and product excellence strategy
Available customizations:
With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the report:
Geographical Analysis
- Further breakdown of the Rest of Europe multiomics market, by country
- Further breakdown of the Rest of Asia Pacific multiomics market, by country
Company Analysis
- Detailed analysis and profiling of additional market players (up to five)
Segment Analysis
- Cross-segment analysis
Get the Full Multiomics Market Report
Full forecast, segment splits, and company analysis for all Multiomics Market.
- Canada Multiomics Market
- US Multiomics Market
- Germany Multiomics Market
- France Multiomics Market
- Italy Multiomics Market
- Spain Multiomics Market
- China Multiomics Market
- Japan Multiomics Market
- South Korea Multiomics Market
- India Multiomics Market
- Australia Multiomics Market
- Brazil Multiomics Market
- Saudi Arabia Multiomics Market
- UAE Multiomics Market
- Rest Of Europe Multiomics Market
- Rest Of Asia Pacific Multiomics Market
- Rest Of Latin America Multiomics Market
- Rest Of GCC Countries Multiomics Market
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This Report
